acoramidis hydrochloride

all catalysts(0)

nothing on the calendar yet

News(7)

• BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
  BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.
  biospace · 4h ago
• 5 companies advancing ATTR assets in the wake of Wainua’s fail
  The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five con…
  biospace · 9d ago
• Alnylam plunges as earnings deliver ‘one-two punch’
  The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
  biopharma_dive · 12d ago
• Biotechs bring big launches and pharma rivalries into Q2 earnings period
  With the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.
  biospace · 14d ago
• Pfizer deals extend patent life for a top-selling rare disease drug
  Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
  biopharma_dive · 3mo ago
• Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
  Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
  biopharma_dive · 3mo ago
• STAT+: Astellas retries XLMTM gene therapy after deaths
  Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
  stat · 3mo ago